Beth Israel Deaconess Medical Center
Boston, MA
Filters
Save & Share
Clear Filters
Diagnosis
Treatment History
BCMA Therapy
This stands for B Cell Maturation Antigen (BCMA) and includes treatments such as ide-cel, cilta-cel or belantamab mafodotin.
Not currently accepting
KarMMa-2
Phase 2 Clinical Trial Studying the Safety and Efficacy of bb2121 in Participants with Relapsed and Refractory Multiple Myeloma or Clinical High-Risk Multiple Myeloma
Learn more- CAR T Cell
- BCMA
- High Risk
- Phase 2
Not yet accepting
CA088-1005
A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component
Learn more- CAR T Cell
- CELMoD
- GPRC5D
- Phase 1
Accepting patients
Daratumumab Combination Therapy
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Learn more- Monoclonal Antibody
- Proteasome Inhibitor
- CD38
- Phase 2
Not yet accepting
Elranatamab as Consolidation
A Phase 2 Study of Elranatamab as Consolidation After Idecabtagene Vicleucel in Relapsed Refractory Multiple Myeloma
Learn more- Bispecific Antibody
- BCMA
- CD3
- Phase 2
Not yet accepting
Elotuzumab + Iberdomide Post ABECMA
Elotuzumab + Iberdomide + Dexamethasone Post Ide-Cel in RRMM
Learn more- Monoclonal Antibody
- SLAMF7
- Phase 1/2
Not yet accepting
CARTITUDE-6
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (CARTITUDE-6)
Learn more- Autologous Stem Cell Transplant
- CAR T Cell
- BCMA
- Phase 3
Not yet accepting
iMMAGINE-1
Study of Anitocabtagene-autoleucel in Relapsed or Refractory Multiple Myeloma
Learn more- CAR T Cell
- BCMA
- Phase 2
1 hidden based on your filters. Show All